Global Information
회사소개 | 문의 | 비교리스트

세계의 T세포 치료 시장(-2026년) : 모달리티별, 요법 유형별, 증상별, 지역별 시장 조사, 예측, COVID-19의 누적 영향

T-Cell Therapy Market Research Report by Modality, by Therapy Type, by Indication, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

리서치사 360iResearch LLP
발행일 2021년 11월 상품 코드 1035754
페이지 정보 영문 182 Pages
가격
US $ 3,949 ₩ 4,748,000 Online Access (Single User License - 1 Year)
US $ 4,949 ₩ 5,951,000 PDF (Single User License) + Excel
US $ 5,949 ₩ 7,153,000 PDF (1-5 User License) + Excel
US $ 7,949 ₩ 9,558,000 PDF (Site License) + Excel
US $ 9,949 ₩ 11,963,000 PDF (Enterprise License) + Excel


세계의 T세포 치료 시장(-2026년) : 모달리티별, 요법 유형별, 증상별, 지역별 시장 조사, 예측, COVID-19의 누적 영향 T-Cell Therapy Market Research Report by Modality, by Therapy Type, by Indication, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19
발행일 : 2021년 11월 페이지 정보 : 영문 182 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

T세포 치료 시장 규모는 2020년에 46억 204만 달러, 2021년에 55억 5,466만 달러에 이르고, 연평균 성장률(CAGR) 21.03%로 성장을 지속하여 2026년까지 144억 7,073만 달러에 달할 것으로 예측됩니다.

세계의 T세포 치료(T-Cell Therapy) 시장을 조사했으며, 시장 개요, 시장 성장 촉진요인 및 억제요인 분석, 시장 기회, COVID-19의 영향, 모달리티·요법 유형·증상·지역별 시장 분석, 경쟁 구도, 주요 기업 프로파일 등의 정보를 제공합니다.

목차

제1장 서문

  • 조사 목적
  • 시장 세분화와 범위
  • 조사 대상년도
  • 통화와 가격
  • 언어
  • 제한 사항
  • 전제조건
  • 이해관계자

제2장 조사 방법

  • 정의 : 조사 목적
  • 결정 : 조사 디자인
  • 준비 : 조사 기기
  • 수집 : 데이터 소스
  • 분석 : 데이터 해석
  • 책정 : 데이터 검증
  • 공개 : 조사 보고서
  • 반복 : 보고서 업데이트

제3장 개요

제4장 시장 개요

제5장 시장 인사이트

  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
    • 과제
  • COVID-19의 누적 영향

제6장 모달리티별, T세포 치료 시장

  • 상업
  • 연구

제7장 요법 유형별, T세포 치료 시장

  • CART 세포 치료
  • T세포 수용체 기반
  • 종양 침윤 림프구 기반

제8장 증상별, T세포 치료 시장

  • 혈액 악성 종양
    • 백혈병
    • 림프종
    • 골수종
  • 고형 종양
    • 뇌/중추신경계
    • 간암
    • 흑색종

제9장 아메리카의 T세포 치료 시장

  • 아르헨티나
  • 브라질
  • 캐나다
  • 멕시코
  • 미국

제10장 아시아태평양의 T세포 치료 시장

  • 호주
  • 중국
  • 인도
  • 인도네시아
  • 일본
  • 말레이시아
  • 필리핀
  • 싱가포르
  • 한국
  • 대만
  • 태국

제11장 유럽, 중동 및 아프리카의 T세포 치료 시장

  • 프랑스
  • 독일
  • 이탈리아
  • 네덜란드
  • 카타르
  • 러시아
  • 사우디아라비아
  • 남아프리카공화국
  • 스페인
  • 아랍에미리트(UAE)
  • 영국

제12장 경쟁 구도

  • FPNV 포지셔닝 매트릭스
    • 상한
    • 사업 전략
    • 제품 만족도
  • 시장 순위 분석
  • 주요 기업별 시장 점유율 분석
  • 경쟁 시나리오
    • 인수합병(M&A)
    • 합의/협업/제휴
    • 신제품 발매와 강화
    • 투자/펀딩
    • 수상/표창/확대

제13장 기업 개요

  • AbbVie Inc.
  • Adaptimmune Therapeutics PLC
  • Amgen Inc.
  • B-MoGen Biotechnologies Inc.
  • bluebird bio, Inc.
  • Bristol Myers Squibb
  • DiaCarta, Inc.
  • Fate Therapeutics Inc.
  • GigaGen Inc.
  • Gilead Sciences, Inc.
  • Merck KGaA
  • NeoStem, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Poseida Therapeutics Inc.
  • Sorrento Therapeutics, Inc.
  • Takara Bio Inc.
  • TCR2 Therapeutics Inc
  • Tessa Therapeutics Pte Ltd
  • Tmunity Therapeutics Inc.

제14장 부록

  • 디스커션 가이드
  • 라이선스와 가격
LSH 21.11.25

LIST OF FIGURES

  • FIGURE 1. GLOBAL T-CELL THERAPY MARKET: RESEARCH PROCESS
  • FIGURE 2. GLOBAL T-CELL THERAPY MARKET: MARKET DYNAMICS
  • FIGURE 3. GLOBAL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2020 VS 2026 (%)
  • FIGURE 4. GLOBAL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2020 VS 2026 (USD MILLION)
  • FIGURE 5. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2026
  • FIGURE 6. GLOBAL T-CELL THERAPY MARKET SIZE, BY COMMERCIALIZED, 2018-2026 (USD MILLION)
  • FIGURE 7. GLOBAL T-CELL THERAPY MARKET SIZE, BY COMMERCIALIZED, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 8. GLOBAL T-CELL THERAPY MARKET SIZE, BY RESEARCH, 2018-2026 (USD MILLION)
  • FIGURE 9. GLOBAL T-CELL THERAPY MARKET SIZE, BY RESEARCH, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 10. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2020 VS 2026 (%)
  • FIGURE 11. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2020 VS 2026 (USD MILLION)
  • FIGURE 12. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2026
  • FIGURE 13. GLOBAL T-CELL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, 2018-2026 (USD MILLION)
  • FIGURE 14. GLOBAL T-CELL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 15. GLOBAL T-CELL THERAPY MARKET SIZE, BY T CELL RECEPTOR-BASED, 2018-2026 (USD MILLION)
  • FIGURE 16. GLOBAL T-CELL THERAPY MARKET SIZE, BY T CELL RECEPTOR-BASED, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 17. GLOBAL T-CELL THERAPY MARKET SIZE, BY TUMOR INFILTRATING LYMPHOCYTES-BASED, 2018-2026 (USD MILLION)
  • FIGURE 18. GLOBAL T-CELL THERAPY MARKET SIZE, BY TUMOR INFILTRATING LYMPHOCYTES-BASED, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 19. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2020 VS 2026 (%)
  • FIGURE 20. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2020 VS 2026 (USD MILLION)
  • FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2026
  • FIGURE 22. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2026 (USD MILLION)
  • FIGURE 23. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 24. GLOBAL T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2026 (USD MILLION)
  • FIGURE 25. GLOBAL T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 26. GLOBAL T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, 2018-2026 (USD MILLION)
  • FIGURE 27. GLOBAL T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 28. GLOBAL T-CELL THERAPY MARKET SIZE, BY MYELOMA, 2018-2026 (USD MILLION)
  • FIGURE 29. GLOBAL T-CELL THERAPY MARKET SIZE, BY MYELOMA, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 30. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2026 (USD MILLION)
  • FIGURE 31. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 32. GLOBAL T-CELL THERAPY MARKET SIZE, BY BRAIN & CENTRAL NERVOUS SYSTEM, 2018-2026 (USD MILLION)
  • FIGURE 33. GLOBAL T-CELL THERAPY MARKET SIZE, BY BRAIN & CENTRAL NERVOUS SYSTEM, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 34. GLOBAL T-CELL THERAPY MARKET SIZE, BY LIVER CANCER, 2018-2026 (USD MILLION)
  • FIGURE 35. GLOBAL T-CELL THERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 36. GLOBAL T-CELL THERAPY MARKET SIZE, BY MELANOMA, 2018-2026 (USD MILLION)
  • FIGURE 37. GLOBAL T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 38. AMERICAS T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 39. ARGENTINA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 40. BRAZIL T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 41. CANADA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 42. MEXICO T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 43. UNITED STATES T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 44. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 45. AUSTRALIA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 46. CHINA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 47. INDIA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 48. INDONESIA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 49. JAPAN T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 50. MALAYSIA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 51. PHILIPPINES T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 52. SINGAPORE T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 53. SOUTH KOREA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 54. TAIWAN T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 55. THAILAND T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 56. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 57. FRANCE T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 58. GERMANY T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 59. ITALY T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 60. NETHERLANDS T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 61. QATAR T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 62. RUSSIA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 63. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 64. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 65. SPAIN T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 66. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 67. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 68. GLOBAL T-CELL THERAPY MARKET: FPNV POSITIONING MATRIX
  • FIGURE 69. GLOBAL T-CELL THERAPY MARKET: SHARE, BY KEY PLAYER, 2020
  • FIGURE 70. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL T-CELL THERAPY MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL T-CELL THERAPY MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2026 (USD MILLION)
  • TABLE 4. GLOBAL T-CELL THERAPY MARKET SIZE, BY COMMERCIALIZED, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 5. GLOBAL T-CELL THERAPY MARKET SIZE, BY RESEARCH, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 6. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
  • TABLE 7. GLOBAL T-CELL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 8. GLOBAL T-CELL THERAPY MARKET SIZE, BY T CELL RECEPTOR-BASED, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 9. GLOBAL T-CELL THERAPY MARKET SIZE, BY TUMOR INFILTRATING LYMPHOCYTES-BASED, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 10. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2026 (USD MILLION)
  • TABLE 11. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 12. GLOBAL T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 13. GLOBAL T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 14. GLOBAL T-CELL THERAPY MARKET SIZE, BY MYELOMA, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 15. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 16. GLOBAL T-CELL THERAPY MARKET SIZE, BY BRAIN & CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 17. GLOBAL T-CELL THERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 18. GLOBAL T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 19. AMERICAS T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 20. ARGENTINA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 21. BRAZIL T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 22. CANADA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 23. MEXICO T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 24. UNITED STATES T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 25. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 26. AUSTRALIA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 27. CHINA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 28. INDIA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 29. INDONESIA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 30. JAPAN T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 31. MALAYSIA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 32. PHILIPPINES T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 33. SINGAPORE T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 34. SOUTH KOREA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 35. TAIWAN T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 36. THAILAND T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 37. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 38. FRANCE T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 39. GERMANY T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 40. ITALY T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 41. NETHERLANDS T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 42. QATAR T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 43. RUSSIA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 44. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 45. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 46. SPAIN T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 47. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 48. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 49. GLOBAL T-CELL THERAPY MARKET: SCORES
  • TABLE 50. GLOBAL T-CELL THERAPY MARKET: BUSINESS STRATEGY
  • TABLE 51. GLOBAL T-CELL THERAPY MARKET: PRODUCT SATISFACTION
  • TABLE 52. GLOBAL T-CELL THERAPY MARKET: RANKING
  • TABLE 53. GLOBAL T-CELL THERAPY MARKET: SHARE, BY KEY PLAYER, 2020
  • TABLE 54. GLOBAL T-CELL THERAPY MARKET: MERGER & ACQUISITION
  • TABLE 55. GLOBAL T-CELL THERAPY MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 56. GLOBAL T-CELL THERAPY MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 57. GLOBAL T-CELL THERAPY MARKET: INVESTMENT & FUNDING
  • TABLE 58. GLOBAL T-CELL THERAPY MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 59. GLOBAL T-CELL THERAPY MARKET: LICENSE & PRICING

The Global T-Cell Therapy Market size was estimated at USD 4,602.04 million in 2020 and expected to reach USD 5,554.66 million in 2021, at a CAGR 21.03% to reach USD 14,470.73 million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the T-Cell Therapy to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Modality, the market was studied across Commercialized and Research.
  • Based on Therapy Type, the market was studied across CAR T-cell Therapy, T Cell Receptor-based, and Tumor Infiltrating Lymphocytes-based.
  • Based on Indication, the market was studied across Hematologic Malignancies and Solid Tumors. The Hematologic Malignancies is further studied across Leukemia, Lymphoma, and Myeloma. The Solid Tumors is further studied across Brain & Central Nervous System, Liver Cancer, and Melanoma.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the T-Cell Therapy Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor's strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global T-Cell Therapy Market, including AbbVie Inc., Adaptimmune Therapeutics PLC, Amgen Inc., B-MoGen Biotechnologies Inc., bluebird bio, Inc., Bristol Myers Squibb, DiaCarta, Inc., Fate Therapeutics Inc., GigaGen Inc., Gilead Sciences, Inc., Merck KGaA, NeoStem, Inc., Novartis AG, Pfizer Inc., Poseida Therapeutics Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., TCR2 Therapeutics Inc, Tessa Therapeutics Pte Ltd, and Tmunity Therapeutics Inc..

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global T-Cell Therapy Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global T-Cell Therapy Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global T-Cell Therapy Market?
  • 4. What is the competitive strategic window for opportunities in the Global T-Cell Therapy Market?
  • 5. What are the technology trends and regulatory frameworks in the Global T-Cell Therapy Market?
  • 6. What is the market share of the leading vendors in the Global T-Cell Therapy Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global T-Cell Therapy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Define: Research Objective
  • 2.3. Determine: Research Design
  • 2.4. Prepare: Research Instrument
  • 2.5. Collect: Data Source
  • 2.6. Analyze: Data Interpretation
  • 2.7. Formulate: Data Verification
  • 2.8. Publish: Research Report
  • 2.9. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing approvals along with expanding manufacturing capabilities
      • 5.1.1.2. COVID-19 pandemic triggered the investment flow
      • 5.1.1.3. Alarming rate of increase in prevalence of cancers
    • 5.1.2. Restraints
      • 5.1.2.1. Limitations of CAR T-cell immunotherapy including paucity of safe tumour-specific targets, and inadequate homing of CAR T-cells to tumour deposits
    • 5.1.3. Opportunities
      • 5.1.3.1. Immuno-oncology sector booming with R&D funding
      • 5.1.3.2. Expanding gene therapy marketspace
    • 5.1.4. Challenges
      • 5.1.4.1. Safety issues and possible side-effects
  • 5.2. Cumulative Impact of COVID-19

6. T-Cell Therapy Market, by Modality

  • 6.1. Introduction
  • 6.2. Commercialized
  • 6.3. Research

7. T-Cell Therapy Market, by Therapy Type

  • 7.1. Introduction
  • 7.2. CAR T-cell Therapy
  • 7.3. T Cell Receptor-based
  • 7.4. Tumor Infiltrating Lymphocytes-based

8. T-Cell Therapy Market, by Indication

  • 8.1. Introduction
  • 8.2. Hematologic Malignancies
    • 8.2.1. Leukemia
    • 8.2.2. Lymphoma
    • 8.2.3. Myeloma
  • 8.3. Solid Tumors
    • 8.3.1. Brain & Central Nervous System
    • 8.3.2. Liver Cancer
    • 8.3.3. Melanoma

9. Americas T-Cell Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific T-Cell Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand

11. Europe, Middle East & Africa T-Cell Therapy Market

  • 11.1. Introduction
  • 11.2. France
  • 11.3. Germany
  • 11.4. Italy
  • 11.5. Netherlands
  • 11.6. Qatar
  • 11.7. Russia
  • 11.8. Saudi Arabia
  • 11.9. South Africa
  • 11.10. Spain
  • 11.11. United Arab Emirates
  • 11.12. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
    • 12.1.1. Quadrants
    • 12.1.2. Business Strategy
    • 12.1.3. Product Satisfaction
  • 12.2. Market Ranking Analysis
  • 12.3. Market Share Analysis, By Key Player
  • 12.4. Competitive Scenario
    • 12.4.1. Merger & Acquisition
    • 12.4.2. Agreement, Collaboration, & Partnership
    • 12.4.3. New Product Launch & Enhancement
    • 12.4.4. Investment & Funding
    • 12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles

  • 13.1. AbbVie Inc.
  • 13.2. Adaptimmune Therapeutics PLC
  • 13.3. Amgen Inc.
  • 13.4. B-MoGen Biotechnologies Inc.
  • 13.5. bluebird bio, Inc.
  • 13.6. Bristol Myers Squibb
  • 13.7. DiaCarta, Inc.
  • 13.8. Fate Therapeutics Inc.
  • 13.9. GigaGen Inc.
  • 13.10. Gilead Sciences, Inc.
  • 13.11. Merck KGaA
  • 13.12. NeoStem, Inc.
  • 13.13. Novartis AG
  • 13.14. Pfizer Inc.
  • 13.15. Poseida Therapeutics Inc.
  • 13.16. Sorrento Therapeutics, Inc.
  • 13.17. Takara Bio Inc.
  • 13.18. TCR2 Therapeutics Inc
  • 13.19. Tessa Therapeutics Pte Ltd
  • 13.20. Tmunity Therapeutics Inc.

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing
Back to Top
전화 문의
F A Q